Brief Summary
ADG206 is an activatable prodrug form of a fully human monoclonal antibodya protein made by the immune system to fight against harmful substances (antigens), such as bacteria or viruses (mAb) of the immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137 (CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of advancedat a late stage, far along malignancies.
Intervention / Treatment
- Drug: ADG206
Inclusion Criteria:
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status ≤1.
- Subjects with advanced or metastatic solid tumors (except thymic tumors), which have progressed after all standard therapies, or no further standard therapies exists.
- At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
- Adequate organ function.
- Woman of childbearing potential must agree to use 2 methods of acceptable contraception from screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening until 6 months after the last dosethe amount of medication taken of study drug.
- Male subjects who are sexually active with a female partner of childbearing potential must agree to use a barrier contraception.